AIM ImmunoTech Net Profit Margin Growth & History (AIM)
AIM ImmunoTech's net profit margin was −15,861.36% for fiscal 2025.
View full AIM ImmunoTech company overviewAIM ImmunoTech annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −15,861.36% | −5673.13 pp |
| 2024 | 2024-12-31 | −10,188.24% | +4149.39 pp |
| 2023 | 2023-12-31 | −14,337.62% | −546.84 pp |
| 2022 | 2022-12-31 | −13,790.78% | +377.37 pp |
| 2021 | 2021-12-31 | −14,168.15% | −5333.79 pp |
| 2020 | 2020-12-31 | −8,834.36% | −2117.21 pp |
| 2019 | 2019-12-31 | −6,717.14% | −4039.49 pp |
| 2018 | 2018-12-31 | −2,677.66% | −787.73 pp |
| 2017 | 2017-12-31 | −1,889.93% | +6264.42 pp |
| 2016 | 2016-12-31 | −8,154.35% | +3296.78 pp |
| 2015 | 2015-12-31 | −11,451.13% | −2593.26 pp |
| 2014 | 2014-12-31 | −8,857.87% | +1958.80 pp |
| 2013 | 2013-12-31 | −10,816.67% | −2669.25 pp |
| 2012 | 2012-12-31 | −8,147.42% | −2548.04 pp |
| 2011 | 2011-12-31 | −5,599.38% | +4130.99 pp |
| 2010 | 2010-12-31 | −9,730.37% | −3261.90 pp |
| 2009 | 2009-12-31 | −6,468.47% | — |
AIM ImmunoTech quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −14,569.23% | −3393.23 pp |
| Q1 2026 | 2026-03-31 | −13,740.91% | +9415.34 pp |
| Q4 2025 | 2025-12-31 | −19,880.95% | −6620.95 pp |
| Q3 2025 | 2025-09-30 | −12,630.77% | −2059.34 pp |
| Q2 2025 | 2025-06-30 | −11,176.00% | −7504.00 pp |
| Q1 2025 | 2025-03-31 | −23,156.25% | −8613.75 pp |
| Q4 2024 | 2024-12-31 | −13,260.00% | +6087.69 pp |
| Q3 2024 | 2024-09-30 | −10,571.43% | +6419.88 pp |
| Q2 2024 | 2024-06-30 | −3,672.00% | +8016.10 pp |
| Q1 2024 | 2024-03-31 | −14,542.50% | −7071.07 pp |
| Q4 2023 | 2023-12-31 | −19,347.69% | −11647.69 pp |
| Q3 2023 | 2023-09-30 | −16,991.30% | +13413.46 pp |
| Q2 2023 | 2023-06-30 | −11,688.10% | +4481.90 pp |
| Q1 2023 | 2023-03-31 | −7,471.43% | +4104.33 pp |
| Q4 2022 | 2022-12-31 | −7,700.00% | +3762.75 pp |
| Q3 2022 | 2022-09-30 | −30,404.76% | −18810.82 pp |
| Q2 2022 | 2022-06-30 | −16,170.00% | +9377.83 pp |
| Q1 2022 | 2022-03-31 | −11,575.76% | +1206.39 pp |
| Q4 2021 | 2021-12-31 | −11,462.75% | −2138.94 pp |
| Q3 2021 | 2021-09-30 | −11,593.94% | −2410.61 pp |
| Q2 2021 | 2021-06-30 | −25,547.83% | −17122.83 pp |
| Q1 2021 | 2021-03-31 | −12,782.14% | −4319.92 pp |
| Q4 2020 | 2020-12-31 | −9,323.81% | — |
| Q3 2020 | 2020-09-30 | −9,183.33% | −4350.55 pp |
| Q2 2020 | 2020-06-30 | −8,425.00% | −1404.31 pp |
| Q1 2020 | 2020-03-31 | −8,462.22% | — |
| Q3 2019 | 2019-09-30 | −4,832.79% | +3267.21 pp |
| Q2 2019 | 2019-06-30 | −7,020.69% | +297.49 pp |
| Q4 2018 | 2018-12-31 | −675.42% | +3310.58 pp |
| Q3 2018 | 2018-09-30 | −8,100.00% | −6708.89 pp |
| Q2 2018 | 2018-06-30 | −7,318.18% | −6288.60 pp |
| Q1 2018 | 2018-03-31 | −4,844.64% | −1486.31 pp |
| Q4 2017 | 2017-12-31 | −3,986.00% | +3345.25 pp |
| Q3 2017 | 2017-09-30 | −1,391.11% | +11617.98 pp |
| Q2 2017 | 2017-06-30 | −1,029.58% | +7657.09 pp |
| Q1 2017 | 2017-03-31 | −3,358.33% | +2190.38 pp |
| Q4 2016 | 2016-12-31 | −7,331.25% | +4287.27 pp |
| Q3 2016 | 2016-09-30 | −13,009.09% | +3525.69 pp |
| Q2 2016 | 2016-06-30 | −8,686.67% | +1621.84 pp |
| Q1 2016 | 2016-03-31 | −5,548.72% | +4020.73 pp |
| Q4 2015 | 2015-12-31 | −11,618.52% | −478.52 pp |
| Q3 2015 | 2015-09-30 | −16,534.78% | −7197.00 pp |
| Q2 2015 | 2015-06-30 | −10,308.51% | +3458.16 pp |
| Q1 2015 | 2015-03-31 | −9,569.44% | −4522.08 pp |
| Q4 2014 | 2014-12-31 | −11,140.00% | −2265.00 pp |
| Q3 2014 | 2014-09-30 | −9,337.78% | +4928.89 pp |
| Q2 2014 | 2014-06-30 | −13,766.67% | −1869.44 pp |
| Q1 2014 | 2014-03-31 | −5,047.37% | +3550.25 pp |
| Q4 2013 | 2013-12-31 | −8,875.00% | +1425.00 pp |
| Q3 2013 | 2013-09-30 | −14,266.67% | +2623.08 pp |
| Q2 2013 | 2013-06-30 | −11,897.22% | −5774.77 pp |
| Q1 2013 | 2013-03-31 | −8,597.62% | −5392.06 pp |
| Q4 2012 | 2012-12-31 | −10,300.00% | −2102.63 pp |
| Q3 2012 | 2012-09-30 | −16,889.74% | −10800.85 pp |
| Q2 2012 | 2012-06-30 | −6,122.45% | +249.77 pp |
| Q1 2012 | 2012-03-31 | −3,205.56% | −1143.65 pp |
| Q4 2011 | 2011-12-31 | −8,197.37% | +1069.30 pp |
| Q3 2011 | 2011-09-30 | −6,088.89% | +4876.83 pp |
| Q2 2011 | 2011-06-30 | −6,372.22% | −2918.56 pp |
| Q1 2011 | 2011-03-31 | −2,061.90% | +14750.60 pp |
| Q4 2010 | 2010-12-31 | −9,266.67% | — |
| Q3 2010 | 2010-09-30 | −10,965.71% | — |
| Q2 2010 | 2010-06-30 | −3,453.66% | — |
| Q1 2010 | 2010-03-31 | −16,812.50% | — |
AIM ImmunoTech net profit margin trends
Over the last five fiscal years, AIM ImmunoTech's net profit margin decreased from −8,834.36% to −15,861.36%, a change of −7027.01 percentage points. The latest reported quarter, Q2 2026, shows −14,569.23%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AIM ImmunoTech source filings ↗